| 贾新立,郭银谋,何世威,等.安罗替尼三线治疗晚期转移性非小细胞肺癌的近期疗效及安全性分析[J].安徽医药,2021,25(11):2309-2312. |
| 安罗替尼三线治疗晚期转移性非小细胞肺癌的近期疗效及安全性分析 |
| Analysis of the short-term efficacy and safety of anlotinib as a third-line treatment of advanced metastatic non-small cell lung cancer |
| |
| DOI：10.3969/j.issn.1009-6469.2021.11.045 |
| 中文关键词: 癌，非小细胞肺 安罗替尼 临床疗效 不良反应 |
| 英文关键词: Carcinoma,non-small-cell lung Anlotinib Clinical efficacy Adverse reactions |
| 基金项目: |
|
| 摘要点击次数: 1284 |
| 全文下载次数: 560 |
| 中文摘要: |
| 目的评估安罗替尼三线治疗晚期转移性非小细胞肺癌( NSCLC)病人的临床疗效及安全性。方法收集 2018年 1月至 2019年 6月在商丘市第三人民医院收治的接受安罗替尼治疗的晚期转移性 NSCLC病人 37例。收集病人临床资料和服药期间主要不良反应。比较治疗前后外周血中癌胚抗原( CEA)水平和 Karnofsky功能状态(KPS)评分，分析安罗替尼的近期疗效与病人一般临床资料的相关性。结果安罗替尼治疗 2个疗程后客观有效率( ORR)为 40.5%，疾病控制率( DCR)为 75.7%；治疗后血清 CEA水平为( 12.6±3.5)ng/mL低于治疗前( 17.9±4.2)ng/mL，治疗后病人的 KPS评分( 76.8±11.4)分高于治疗前( 71.5± |
| 英文摘要: |
| Objective To evaluate the clinical efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer. Methods Thirty-seven patients with advanced metastatic NSCLC who were treated with anlotinib in the Third People's Hospital ofShangqiu from January 2018 to June 2019 were collected. The clinical data and main adverse reactions during medication of patientswere collected. The carcinoembryonic antigen (CEA) level and Karnofsky functional status (KPS) score in peripheral blood were compared before and after treatment, and the correlation between the short-term efficacy of anlotinib and the general clinical data of patients was analyzed.Results After 2 courses of anlotinib treatment, the objective response rate (ORR) was 40.5% and the disease control rate (DCR) was 75.7%. Serum CEA level after treatment was (12.6±3.5) ng/mL lower than before treatment (17.9±4.2) ng/mL. TheKPS score of patients after treatment (76.8±11.4) was higher than that before treatment (71.5±10.7). During treatment, the main adversereactions were neutropenia (32.4%) and thrombocytopenia (21.6%), respectively. The clinical stage Ⅲb DCR patients accounted for90.0%, which was significantly higher than the clinical stage Ⅳ stage (58.8%). Driver gene-positive DCR patients accounted for 95.0%, which was significantly higher than driver gene-negative (52.9%).Conclusion Anlotinib multiline treatment for patients with advanced non-small cell lung cancer can reduce CEA levels, DCR is higher and adverse reactions of grade Ⅲ-Ⅳ are less. It is worthy of clinical promotion. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
